Article info
PDFReview
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Correspondence to Dr Marija Cauchi, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, University Hospital of Wales, Cardiff CF10 3AT, UK; cauchim1{at}cardiff.ac.uk
Citation
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
Publication history
- Accepted June 8, 2022
- First published July 21, 2022.
Online issue publication
September 26, 2022
Article Versions
- Previous version (21 July 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Update on disease-modifying therapies for multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Disease modifying therapies for relapsing multiple sclerosis
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis
- Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
- Disease modification in multiple sclerosis: an update